Last Updated: June 27, 2026

LANREOTIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lanreotide patents expire, and when can generic versions of Lanreotide launch?

Lanreotide is a drug marketed by Invagen Pharms and is included in two NDAs.

The generic ingredient in LANREOTIDE is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lanreotide

A generic version of LANREOTIDE was approved as lanreotide acetate by INVAGEN PHARMS on December 17th, 2021.

  Start Trial

AI Deep Research
Ask!
Questions you can ask:
  • What is the 5 year forecast for LANREOTIDE?
  • What are the global sales for LANREOTIDE?
  • What is Average Wholesale Price for LANREOTIDE?
Summary for LANREOTIDE
US Patents:0
Applicants:1
NDAs:2
Drug Prices: Drug price information for LANREOTIDE
DailyMed Link:LANREOTIDE at DailyMed
Drug patent expirations by year for LANREOTIDE
Drug Prices for LANREOTIDE

See drug prices for LANREOTIDE

US Patents and Regulatory Information for LANREOTIDE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Invagen Pharms LANREOTIDE ACETATE lanreotide acetate SOLUTION;SUBCUTANEOUS 217193-001 May 21, 2024 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Invagen Pharms LANREOTIDE ACETATE lanreotide acetate SOLUTION;SUBCUTANEOUS 215395-002 Dec 17, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Invagen Pharms LANREOTIDE ACETATE lanreotide acetate SOLUTION;SUBCUTANEOUS 215395-001 Dec 17, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links